Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Equity-to-Asset : -2.49 (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cancer Prevention Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2016 was $-22.85 Mil. Cancer Prevention Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2016 was $9.19 Mil. Therefore, Cancer Prevention Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2016 was -2.49.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

CPP's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Cancer Prevention Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Equity-to-Asset Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Equity-to-Asset

-5.06

-3.28

-11.45

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Equity-to-Asset	Get a 7-Day Free Trial			-3.28	-	-6.02	-11.45	-2.49

Competitive Comparison of Cancer Prevention Pharmaceuticals's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Equity-to-Asset falls into.

Cancer Prevention Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cancer Prevention Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Equity to Asset (A: Dec. 2015 )	=	Total Stockholders Equity	/	Total Assets
	=	-21.182	/	1.85
	=	-11.45

Cancer Prevention Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2016 is calculated as

Equity to Asset (Q: Mar. 2016 )	=	Total Stockholders Equity	/	Total Assets
	=	-22.85	/	9.189
	=	-2.49

Cancer Prevention Pharmaceuticals (AMEX:CPP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cancer Prevention Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.